Tau-Based Treatment Strategies in Neurodegenerative Diseases

Neurotherapeutics

Volumn 5, Issue 3, 2008, Pages 443-457

  Schneider, Anja ^a,b   Mandelkow, Eckhard ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c MAX PLANCK UNIT FOR STRUCTURAL MOLECULAR BIOLOGY   (Germany)

Author keywords

aggregation; Alzheimer's disease; neurodegeneration; phosphorylation; Tau; therapy

Indexed keywords

ANILINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; AR A014418; CALPASTATIN; FLAVOPIRIDOL; HYDRAZIDE DERIVATIVE; INDIRUBIN; ISOQUINOLINE DERIVATIVE; LITHIUM; OKADAIC ACID; PACLITAXEL; PHENYLTHIAZOLYLHYDRAZIDE DERIVATIVE; PHOSPHATASE; STAUROSPORINE; SULFONAMIDE; TAU PROTEIN; THIAZOLE DERIVATIVE; TX 67; VALPROIC ACID;

ARTICLE; CYTOLOGY; DEGENERATIVE DISEASE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TAUOPATHY; VACCINATION;

ANIMALS; ANTIBODIES; BRAIN; HUMANS; IMMUNOTHERAPY; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; TAU PROTEINS;

EID: 46749113005     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.05.006     Document Type: Article

References (227)

1. Weingarten M.D., Lockwood A.H., Hwo S.Y., and Kirschner M.W. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 72 (1975) 1858-1862
2. Cleveland D.W., Hwo S.Y., and Kirschner M.W. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol 116 (1977) 207-225
3. Drubin D.G., Caput D., and Kirschner M.W. Studies on the expression of the microtubule-associated protein, tau, during mouse brain development, with newly isolated complementary DNA probes. J Cell Biol 98 (1984) 1090-1097
4. Binder L.I., Frankfurter A., and Rebhun L.I. The distribution of tau in the mammalian central nervous system. J Cell Biol 101 (1985) 1371-1378
5. Kirschner M., and Mitchison T. Beyond self-assembly: from microtubules to morphogenesis. Cell 45 (1986) 329-342
6. Caceres A., and Kosik K.S. Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature 343 (1990) 461-463
7. Sheetz M.P., Vale R., Schnapp B., et al. Vesicle movements and microtubule-based motors. J Cell Sci Suppl 5 (1986) 181-188
8. Sloboda R.D., Rudolph S.A., Rosenbaum J.L., and Greengard P. Cyclic AMP-dependent endogenous phosphorylation of a microtubule-associated protein. Proc Natl Acad Sci U S A 72 (1975) 177-181
9. Mandell J.W., and Banker G.A. Microtubule-associated proteins, phosphorylation gradients, and the establishment of neuronal polarity. Perspect Dev Neurobiol 4 (1996) 125-135
10. Lee G., Cowan N., and Kirschner M. The primary structure and heterogeneity of tau protein from mouse brain. Science 239 (1988) 285-288
11. Schweers O., Schönbrunn-Hanebeck E., Marx A., and Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for β-structure. J Biol Chem 269 (1994) 24290-24297
12. Andreadis A., Brown W.M., and Kosik K.S. Structure and novel exons of the human tau gene. Biochemistry 31 (1992) 10626-10633
13. Goedert M., Spillantini M.G., Jakes R., Rutherford D., and Crowther R.A. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3 (1989) 519-526
14. Preuss U., Biernat J., Mandelkow E.M., and Mandelkow E. The 'jaws' model of tau-microtubule interaction examined in CHO cells. J Cell Sci 110 (1997) 789-800
15. Butner K.A., and Kirschner M.W. Tau protein binds to microtubules through a flexible array of distributed weak sites. J Cell Biol 115 (1991) 717-730
16. Goode B.L., and Feinstein S.C. Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol 124 (1994) 769-782
17. Panda D., Samuel J.C., Massie M., Feinstein S.C., and Wilson L. Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. Proc Natl Acad Sci U S A 100 (2003) 9548-9553
18. Nothias F., Boyne L., Murray M., Tessler A., and Fischer I. The expression and distribution of tau proteins and messenger RNA in rat dorsal root ganglion neurons during development and regeneration. Neuroscience 66 (1995) 707-719
19. Biernat J., Gustke N., Drewes G., Mandelkow E.M., and Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11 (1993) 153-163
20. Bramblett G.T., Goedert M., Jakes R., Merrick S.E., Trojanowski J.Q., and Lee V.M. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 10 (1993) 1089-1099
21. Hirokawa N., Shiomura Y., and Okabe S. Tau proteins: the molecular structure and mode of binding on microtubules. J Cell Biol 107 (1988) 1449-1459
22. Chen J., Kanai Y., Cowan N.J., and Hirokawa N. Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature 360 (1992) 674-677
23. Sontag E., Nunbhakdi-Craig V., Lee G., Bloom G.S., and Mumby M.C. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 17 (1996) 1201-1207
24. Shimura H., Miura-Shimura Y., and Kosik K.S. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem 279 (2004) 17957-17962
25. Selden S.C., and Pollard T.D. Phosphorylation of microtubule-associated proteins regulates their interaction with actin filaments. J Biol Chem 258 (1983) 7064-7071
26. Ebneth A., Godemann R., Stamer K., Illenberger S., Trinczek B., and Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 143 (1998) 777-794
27. Mandelkow E.M., Stamer K., Vogel R., Thies E., and Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24 (2003) 1079-1085
28. Seitz A., Kojima H., Oiwa K., Mandelkow E.M., Song Y.H., and Mandelkow E. Single-molecule investigation of the interference between kinesin, tau and MAP2c. EMBO J 21 (2002) 4896-4905
29. Dixit R., Ross J.L., Goldman Y.E., and Holzbaur E.L. Differential regulation of dynein and kinesin motor proteins by tau. Science 319 (2008) 1086-1089
30. Stamer K., Vogel R., Thies E., Mandelkow E., and Mandelkow E.M. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156 (2002) 1051-1063
31. Thies E., and Mandelkow E.M. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci 27 (2007) 2896-2907
32. Brion J.P., Flament-Durand J., and Dustin P. Alzheimer's disease and tau proteins. Lancet 2 8515 (1986) 1098
33. Grundke-Iqbal I., Iqbal K., Quinlan M., Tung Y.C., Zaidi M.S., and Wisniewski H.M. Microtubule-associated protein tau: a component of Alzheimer paired helical filaments. J Biol Chem 261 (1986) 6084-6089
34. Hirano A. Hirano bodies and related neuronal inclusions. Neuropathol Appl Neurobiol 20 (1994) 3-11
35. Arima K. Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies. Neuropathology 26 (2006) 475-483
36. Berry R.W., Quinn B., Johnson N., Cochran E.J., Ghoshal N., and Binder L.I. Pathological glial tau accumulations in neurodegenerative disease: review and case report. Neurochem Int 39 (2001) 469-479
37. Thal D.R., Holzer M., Rüb U., et al. Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Exp Neurol 163 (2000) 98-110
38. Lane R.M., Potkin S.G., and Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 9 (2006) 101-124
39. 1-42 in sporadic CJD: a discrimination from Alzheimer's disease?. J Neurol Neurosurg Psychiatry 71 (2001) 401-403
40. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., and Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol 26 (1995) 231-245
41. 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 107 (2000) 563-579
42. Formichi P., Battisti C., Radi E., et al. Cerebrospinal fluid tau, Aβ, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol 208 (2006) 39-46
43. 1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity. J Neural Transm 110 (2003) 1149-1160
44. Blennow K., and Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2 (2003) 605-613
45. Hampel H., Mitchell A., Blennow K., et al. Core biological marker candidates of Alzheimer's disease: perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 111 (2004) 247-272
46. Diniz B.S., Pinto Jr. J.A., and Forlenza O.V. Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease?. A systematic review and meta-analysis of the literature. World J Biol Psychiatry (2008) Jan 29 (Epub ahead of print)
47. Ewers M., Buerger K., Teipel S.J., et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 69 (2007) 2205-2212
48. Buerger K., Ewers M., Andreasen N., et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 65 (2005) 1502-1503
49. Small G.W., Kepe V., Ercoli L.M., et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355 (2006) 2652-2663
50. Klunk W.E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004) 306-319
51. Poorkaj P., Bird T.D., Wijsman E., et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. [Erratum in: Ann Neurol 1998;44:428]. Ann Neurol 43 (1998) 815-825
52. Hutton M., Lendon C.L., Rizzu P., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393 (1998) 702-705
53. Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., and Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 95 (1998) 7737-7741
54. Hasegawa M., Smith M.J., and Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett 437 (1998) 207-210
55. Hong M., Zhukareva V., Vogelsberg-Ragaglia V., et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282 (1998) 1914-1917
56. Dayanandan R., Van Slegtenhorst M., Mack T.G., et al. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett 446 (1999) 228-232
57. Nacharaju P., Lewis J., Easson C., et al. Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett 447 (1999) 195-199
58. Goedert M., Jakes R., and Crowther R.A. Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett 450 (1999) 306-311
59. Gamblin T.C., King M.E., Dawson H., et al. In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. Biochemistry 39 (2000) 6136-6144
60. Barghorn S., Zheng-Fischhöfer Q., Ackmann M., et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry 39 (2000) 11714-11721
61. D'Souza I., Poorkaj P., Hong M., et al. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A 96 (1999) 5598-5603
62. Grover A., DeTure M., Yen S.H., and Hutton M. Effects on splicing and protein function of three mutations in codon N296 of tau in vitro. Neurosci Lett 323 (2002) 33-36
63. Baker M., Litvan I., Houlden H., et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8 (1999) 711-715
64. Houlden H., Baker M., Morris H.R., et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56 (2001) 1702-1706
65. Togo T., Sahara N., Yen S.H., et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 61 (2002) 547-556
66. Anderton B.H., Betts J., Blackstock W.P., et al. Sites of phosphorylation in tau and factors affecting their regulation. Biochem Soc Symp 67 (2001) 73-80
67. Khlistunova I., Biernat J., Wang Y., et al. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 281 (2006) 1205-1214
68. Eckermann K., Mocanu M.M., Khlistunova I., et al. The β-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem 282 (2007) 31755-31765
69. Mocanu M.M., Nissen A., Eckermann K., et al. The potential for β-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci 28 (2008) 737-748
70. Steinhilb M.L., Dias-Santagata D., Fulga T.A., Felch D.L., and Feany M.B. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell 18 (2007) 5060-5068
71. Steinhilb M.L., Dias-Santagata D., Mulkearns E.E., et al. S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. J Neurosci Res 85 (2007) 1271-1278
72. Nishimura I., Yang Y., and Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116 (2004) 671-682
73. Santacruz K., Lewis J., Spires T., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005) 476-481
74. Buée L., Bussière T., Buée-Scherrer V., Delacourte A., and Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33 (2000) 95-130
75. Gong C.X., Liu F., Grundke-Iqbal I., and Iqbal K. Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 112 (2005) 813-838
76. Yang Y.C., Lin C.H., and Lee E.H. Serum- and glucocorticoid-inducible kinase 1 (SGK1) increases neurite formation through microtubule depolymerization by SGK1 and by SGK1 phosphorylation of tau. Mol Cell Biol 26 (2006) 8357-8370
77. Drewes G., Ebneth A., Preuss U., Mandelkow E.M., and Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 89 (1997) 297-308
78. Kishi M., Pan Y.A., Crump J.G., and Sanes J.R. Mammalian SAD kinases are required for neuronal polarization. Science 307 (2005) 929-932
79. Pei J.J., Khatoon S., An W.L., et al. Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol 105 (2003) 381-392
80. Pei J.J., Braak H., An W.L., et al. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res 109 (2002) 45-55
81. Illenberger S., Zheng-Fischhöfer Q., Preuss U., et al. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol Biol Cell 9 (1998) 1495-1512
82. Morishima-Kawashima M., Hasegawa M., Takio K., et al. Hyperphosphorylation of tau in PHF. Neurobiol Aging 16 (1995) 365-371 discussion 371-380
83. Augustinack J.C., Schneider A., Mandelkow E.M., and Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103 (2002) 26-35
84. Drewes G., Trinczek B., Illenberger S., et al. Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark): a novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. J Biol Chem 270 (1995) 7679-7688
85. Oddo S., Caccamo A., Shepherd J.D., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39 (2003) 409-421
86. Schneider A., Biernat J., von Bergen M., Mandelkow E., and Mandelkow E.M. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38 (1999) 3549-3558
87. Khurana V., Lu Y., Steinhilb M.L., Oldham S., Shulman J.M., and Feany M.B. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol 16 (2006) 230-241
88. Kosik K.S., Ahn J., Stein R., and Yeh L.A. Discovery of compounds that will prevent tau pathology. J Mol Neurosci 19 (2002) 261-266
89. Mandelkow E.M., Thies E., Trinczek B., Biernat J., and lkow E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol 167 (2004) 99-110
90. Biernat J., Wu Y.Z., Timm T., et al. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell 13 (2002) 4013-4028
91. Timm T., Li X.Y., Biernat J., et al. MARKK, a Ste20-like kinase, activates the polarity-inducing kinase MARK/PAR-1. EMBO J 22 (2003) 5090-5101
92. Chin J.Y., Knowles R.B., Schneider A., Drewes G., Mandelkow E.M., and Hyman B.T. Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. J Neuropathol Exp Neurol 59 (2000) 966-971
93. Matenia D., Griesshaber B., Li X.Y., et al. PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin. Mol Biol Cell 16 (2005) 4410-4422
94. Draviam V.M., Stegmeier F., Nalepa G., et al. A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling. Nat Cell Biol 9 (2007) 556-564
95. Raman M., Earnest S., Zhang K., Zhao Y., and Cobb M.H. TAO kinases mediate activation of p38 in response to DNA damage. EMBO J 26 (2007) 2005-2014
96. Toshima J., Toshima J.Y., Takeuchi K., Mori R., and Mizuno K. Cofilin phosphorylation and actin reorganization activities of testicular protein kinase 2 and its predominant expression in testicular Sertoli cells. J Biol Chem 276 (2001) 31449-31458
97. Johne C., Matenia D., Li X.Y., Timm T., Balusamy K., and Mandelkow E.M. Spred1 and TESK1: two new interaction partners of the kinase MARKK/TAO1 that link the microtubule and actin cytoskeleton. Mol Biol Cell 19 (2008) 1391-1401
98. LaLonde D.P., Brown M.C., Bouverat B.P., and Turner C.E. Actopaxin interacts with TESK1 to regulate cell spreading on fibronectin. J Biol Chem 280 (2005) 21680-21688
99. Tsumura Y., Toshima J., Leeksma O.C., Ohashi K., and Mizuno K. Sprouty-4 negatively regulates cell spreading by inhibiting the kinase activity of testicular protein kinase. Biochem J 387 (2005) 627-637
100. Heredia L., Helguera P., de Olmos S., et al. Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid β-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease. J Neurosci 26 (2006) 6533-6542
101. Meijer L., Thunnissen A.M., White A.W., et al. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 7 (2000) 51-63
102. Zheng-Fischhöfer Q., Biernat J., Mandelkow E.M., Illenberger S., Godemann R., and Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kinase-3β and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem 252 (1998) 542-552
103. Liu S.J., Zhang J.Y., Li H.L., et al. Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem 279 (2004) 50078-50088
104. Shuntoh H., Sakamoto N., Matsuyama S., et al. Molecular structure of the Cβ catalytic subunit of rat cAMP-dependent protein kinase and differential expression of Cα and Cβ isoforms in rat tissues and cultured cells. Biochim Biophys Acta 1131 (1992) 175-180
105. Pei J.J., Grundke-Iqbal I., Iqbal K., Bogdanovic N., Winblad B., and Cowburn R.F. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res 797 (1998) 267-277
106. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., and Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by in. Nature 405 (2000) 360-364
107. Noble W., Olm V., Takata K., et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38 (2003) 555-565
108. Cruz J.C., Tseng H.C., Goldman J.A., Shih H., and Tsai L.H. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40 (2003) 471-483
109. Lopes J.P., Oliveira C.R., and Agostinho P. Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-β and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies. Cell Mol Neurobiol 27 (2007) 943-957
110. Morfini G., Szebenyi G., Brown H., et al. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J 23 (2004) 2235-2245
111. Hallows J.L., Chen K., DePinho R.A., and Vincent I. Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J Neurosci 23 (2003) 10633-10644
112. Johnson K., Liu L., Majdzadeh N., et al. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3′ substituted indolones as a scaffold for the development of neuroprotective drugs. J Neurochem 93 (2005) 538-548
113. Camins A., Verdaguer E., Folch J., Canudas A.M., and Pallàs M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 19 (2006) 453-460
114. Rosania G.R., Merlie Jr. J., Gray N., Chang Y.T., Schultz P.G., and Heald R. A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts. Proc Natl Acad Sci U S A 96 (1999) 4797-4802
115. Tsai LH. The inducible p25 transgenic mouse as an Alzheimer's disease model. Presented at: Alzheimer's disease: from molecular mechanisms to drug discovery, Cancun, Mexico, Dec 11-17, 2004.
116. Higuchi M., Iwata N., and Saido T.C. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. Biochim Biophys Acta 1751 (2005) 60-67
117. Saez M.E., Ramirez-Lorca R., Moron F.J., and Ruiz A. The therapeutic potential of the calpain family: new aspects. Drug Discov Today 11 (2006) 917-923
118. Vita M., Abdel-Rehim M., Olofsson S., et al. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur J Pharm Sci 25 (2005) 91-103
119. Woodgett J.R. cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol 200 (1991) 564-577
120. Grimes C.A., and Jope R.S. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog Neurobiol 65 (2001) 391-426
121. Doble B.W., and Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116 (2003) 1175-1186
122. Lovestone S., Reynolds C.H., Latimer D., et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 4 (1994) 1077-1086
123. Hong M., and Lee V.M. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272 (1997) 19547-19553
124. Muñoz-Montaño J.R., Moreno F.J., Avila J., and Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett 411 (1997) 183-188
125. Li T., and Paudel H.K. Glycogen synthase kinase 3β phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry 45 (2006) 3125-3133
126. Pei J.J., Tanaka T., Tung Y.C., Braak E., Iqbal K., and Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56 (1997) 70-78
127. Jackson G.R., Wiedau-Pazos M., Sang T.K., et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34 (2002) 509-519
128. Hernández F., Borrell J., Guaza C., Avila J., and Lucas J.J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau filaments. J Neurochem 83 (2002) 1529-1533
129. Lucas J.J., Hernández F., Gómez-Ramos P., Morán M.A., Hen R., and Avila J. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J 20 (2001) 27-39
130. Alvarez G., Muñoz-Montaño J.R., Satrústegui J., Avila J., Bogónez E., and Díaz-Nido J. Regulation of tau phosphorylation and protection against β-amyloid-induced neurodegeneration by lithium: possible implications for Alzheimer's disease. Bipolar Disord 4 (2002) 153-165
131. Churcher I. Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr Top Med Chem 6 (2006) 579-595
132. Bhat R., Xue Y., Berg S., et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278 (2003) 45937-45945
133. Phiel C.J., and Klein P.S. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41 (2001) 789-813
134. Noble W., Planel E., Zehr C., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102 (2005) 6990-6995
135. Sun L., Liu S.Y., Zhou X.W., et al. Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 118 (2003) 1175-1182
136. Vogelsberg-Ragaglia V., Schuck T., Trojanowski J.Q., and Lee V.M. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 168 (2001) 402-412
137. Gong C.X., Shaikh S., Wang J.Z., Zaidi T., Grundke-Iqbal I., and Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 65 (1995) 732-738
138. Pei J.J., Gong C.X., An W.L., et al. Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am J Pathol 163 (2003) 845-858
139. Li L., Sengupta A., Haque N., Grundke-Iqbal I., and Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 566 (2004) 261-269
140. Kampers T., Friedhoff P., Biernat J., Mandelkow E.M., and Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett 399 (1996) 344-349
141. Goedert M., Jakes R., Spillantini M.G., Hasegawa M., Smith M.J., and Crowther R.A. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383 (1996) 550-553
142. Arrasate M., Pérez M., Valpuesta J.M., and Avila J. Role of glycosaminoglycans in determining the helicity of paired helical filaments. Am J Pathol 151 (1997) 1115-1122
143. Wilson D.M., and Binder L.I. Free fatty acids stimulate the polymerization of tau and amyloid β peptides: in vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am J Pathol 150 (1997) 2181-2195
144. 311) forming β structure. Proc Natl Acad Sci U S A 97 (2000) 5129-5134
145. von Bergen M., Barghorn S., Li L., et al. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local β-structure. J Biol Chem 276 (2001) 48165-48174
146. Mandelkow E., von Bergen M., Biernat J., and Mandelkow E.M. Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol 17 (2007) 83-90
147. Wille H., Drewes G., Biernat J., Mandelkow E.M., and Mandelkow E. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol 118 (1992) 573-584
148. Avila J., Santa-María I., Pérez M., Hernández F., and Moreno F. Tau phosphorylation, aggregation, and cell toxicity. J Biomed Biotechnol 2006 (2006) 74539
149. Mi K., and Johnson G.V. The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 3 (2006) 449-463
150. Cotman C.W., Poon W.W., Rissman R.A., and Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp Neurol 64 (2005) 104-112
151. Wang Y.P., Biernat J., Pickhardt M., Mandelkow E., and Mandelkow E.M. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A 104 (2007) 10252-10257
152. Bandyopadhyay B., Li G., Yin H., and Kuret J. Tau aggregation and toxicity in a cell culture model of tauopathy. J Biol Chem 282 (2007) 16454-16464
153. Wischik C.M., Edwards P.C., Lai R.Y., Roth M., and Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 93 (1996) 11213-11218
154. Pickhardt M., Gazova Z., von Bergen M., et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem 280 (2005) 3628-3635
155. Pickhardt M., Larbig G., Khlistunova I., et al. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46 (2007) 10016-10023
156. Bulic B., Pickhardt M., Khlistunova I., et al. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew Chem Int Ed Engl 46 (2007) 9215-9219
157. Pickhardt M., Biernat J., Khlistunova I., et al. N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy. Curr Alzheimer Res 4 (2007) 397-402
158. Meyer B., Klein J., Mayer M., et al. Saturation transfer difference NMR spectroscopy for identifying ligand epitopes and binding specificities. Ernst Schering Res Found Workshop 44 (2004) 149-167
159. Zeiger E., Shelby M.D., Ivett J., and McFee A.F. Mutagenicity testing of 5-(4-nitrophenyl)-2,4-pentadien-1-al (spy dust) and its metabolites in vitro and in vivo. Environ Mutagen 9 (1987) 269-280
160. Hotta N., Sakamoto N., Shigeta Y., Kikkawa R., Goto Y., and Diabetic Neuropathy Study Group in Japan. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. J Diabetes Complications 10 (1996) 168-172
161. Necula M., Chirita C.N., and Kuret J. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry 44 (2005) 10227-10237
162. Chirita C., Necula M., and Kuret J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43 (2004) 2879-2887
163. Honson N.S., Jensen J.R., Darby M.V., and Kuret J. Potent inhibition of tau fibrillization with a multivalent ligand. Biochem Biophys Res Commun 363 (2007) 229-234
164. May B.C., Fafarman A.T., Hong S.B., et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc Natl Acad Sci U S A 100 (2003) 3416-3421
165. Necula M., Kayed R., Milton S., and Glabe C.G. Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282 (2007) 10311-10324
166. Ravikumar B., Duden R., and Rubinsztein D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 11 (2002) 1107-1117
167. Klionsky D.J., and Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science 290 (2000) 1717-1721
168. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., and Rubinsztein D.C. α-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278 (2003) 25009-25013
169. Berger Z., Ravikumar B., Menzies F.M., et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15 (2006) 433-442
170. Tan J.M., Wong E.S., Kirkpatrick D.S., et al. Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet 17 (2008) 431-439
171. Rubinsztein D.C., Ravikumar B., Acevedo-Arozena A., Imarisio S., O'Kane C.J., and Brown S.D. Dyneins, autophagy, aggregation and neurodegeneration. Autophagy 1 (2005) 177-178
172. Rubinsztein D.C., DiFiglia M., Heintz N., et al. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 1 (2005) 11-22
173. Dickey C.A., Dunmore J., Lu B., et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 20 (2006) 753-755
174. Kamal A., Boehm M.F., and Burrows F.J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 10 (2004) 283-290
175. Cripps D., Thomas S.N., Jeng Y., Yang F., Davies P., and Yang A.J. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem 281 (2006) 10825-10838
176. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Titani K., and Ihara Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 10 (1993) 1151-1160
177. Shimura H., Schwartz D., Gygi S.P., and Kosik K.S. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 279 (2004) 4869-4876
178. Dickey C.A., Yue M., Lin W.L., et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci 26 (2006) 6985-6996
179. Petrucelli L., Dickson D., Kehoe K., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13 (2004) 703-714
180. Sahara N., Murayama M., Mizoroki T., et al. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem 94 (2005) 1254-1263
181. Kumar P., Ambasta R.K., Veereshwarayya V., et al. CHIP and HSPs interact with β-APP in a proteasome-dependent manner and influence Aβ metabolism. Hum Mol Genet 16 (2007) 848-864
182. Karsten S.L., Sang T.K., Gehman L.T., et al. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron 51 (2006) 549-560
183. Constam D.B., Tobler A.R., Rensing-Ehl A., Kemler I., Hersh L.B., and Fontana A. Puromycin-sensitive aminopeptidase: sequence analysis, expression, and functional characterization. J Biol Chem 270 (1995) 26931-26939
184. Hersh L.B. Characterization of membrane-bound aminopeptidases from rat brain: identification of the enkephalin-degrading aminopeptidase. J Neurochem 44 (1985) 1427-1435
185. Sengupta S., Horowitz P.M., Karsten S.L., et al. Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. Biochemistry 45 (2006) 15111-15119
186. Park S.Y., and Ferreira A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates β-amyloid-induced neurodegeneration. J Neurosci 25 (2005) 5365-5375
187. Gamblin T.C., Chen F., Zambrano A., et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100 (2003) 10032-10037
188. Rissman R.A., Poon W.W., Blurton-Jones M., et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114 (2004) 121-130
189. Fasulo L., Ugolini G., and Cattaneo A. Apoptotic effect of caspase-3 cleaved tau in hippocampal neurons and its potentiation by tau FTDP-mutation N279K. J Alzheimers Dis 7 (2005) 3-13
190. Chong Y.H., Shin Y.J., Lee E.O., Kayed R., Glabe C.G., and Tenner A.J. ERK1/2 activation mediates Aβ oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem 281 (2006) 20315-20325
191. Nerenberg S.T., and Prasad R. Radioimmunoassays for Ig classes G, A, M, D, and E in spinal fluids: normal values of different age groups. J Lab Clin Med 86 (1975) 887-898
192. Broadwell R.D., and Sofroniew M.V. Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp Neurol 120 (1993) 245-263
193. Zlokovic B.V., Segal M.B., Davson H., Lipovac M.N., Hyman S., and McComb J.G. Circulating neuroactive peptides and the blood-brain and blood-cerebrospinal fluid barriers. Endocrinol Exp 24 (1990) 9-17
194. Poduslo J.F., and Curran G.L. Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport 12 (2001) 3197-3200
195. LaRue B., Hogg E., Sagare A., et al. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-β peptide in wild type and Alzheimer's Tg2576 mice. J Neurosci Methods 138 (2004) 233-242
196. Asuni A.A., Boutajangout A., Quartermain D., and Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27 (2007) 9115-9129
197. Rosenmann H., Grigoriadis N., Karussis D., et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63 (2006) 1459-1467
198. Andoh T., and Kuraishi Y. Expression of Fcε receptor I on primary sensory neurons in mice. Neuroreport 15 (2004) 2029-2031
199. Fabian R.H., and Ritchie T.C. Intraneuronal IgG in the central nervous system. J Neurol Sci 73 (1986) 257-267
200. Fabian R.H., and Petroff G. Intraneuronal IgG in the central nervous system: uptake by retrograde axonal transport. Neurology 37 (1987) 1780-1784
201. Dietzschold B., Kao M., Zheng Y.M., et al. Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. [Erratum in: Proc Natl Acad Sci U S A 1992;89:9365]. Proc Natl Acad Sci U S A 89 (1992) 7252-7256
202. Aihara N., Tanno H., Hall J.J., Pitts L.H., and Noble L.J. Immunocytochemical localization of immunoglobulins in the rat brain: relationship to the blood-brain barrier. J Comp Neurol 342 (1994) 481-496
203. Mohamed H.A., Mosier D.R., Zou L.L., et al. Immunoglobulin Fcγ receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res 69 (2002) 110-116
204. Lobo E.D., Hansen R.J., and Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93 (2004) 2645-2668
205. Masliah E., Rockenstein E., Adame A., et al. Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46 (2005) 857-868
206. Orgogozo J.M., Gilman S., Dartigues J.F., et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61 (2003) 46-54
207. Connell J.W., Rodriguez-Martin T., Gibb G.M., et al. Quantitative analysis of tau isoform transcripts in sporadic tauopathies. Brain Res Mol Brain Res 137 (2005) 104-109
208. Ishizawa K., Ksiezak-Reding H., Davies P., et al. A double-labeling immunohistochemical study of tau exon 10 in Alzheimer's disease, progressive supranuclear palsy and Pick's disease. Acta Neuropathol 100 (2000) 235-244
209. Buée L., and Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol 9 (1999) 681-693
210. Takanashi M., Mori H., Arima K., Mizuno Y., and Hattori N. Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. Brain Res Mol Brain Res 104 (2002) 210-219
211. Chambers C.B., Lee J.M., Troncoso J.C., Reich S., and Muma N.A. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol 46 (1999) 325-332
212. Caffrey T.M., Joachim C., Paracchini S., Esiri M.M., and Wade-Martins R. Haplotype-specific expression of exon 10 at the human MAPT locus. Hum Mol Genet 15 (2006) 3529-3537
213. Boutajangout A., Boom A., Leroy K., and Brion J.P. Expression of tau mRNA and soluble tau isoforms in affected and non-affected brain areas in Alzheimer's disease. FEBS Lett 576 (2004) 183-189
214. Glatz D.C., Rujescu D., Tang Y., et al. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J Neurochem 96 (2006) 635-644
215. Kalbfuss B., Mabon S.A., and Misteli T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J Biol Chem 276 (2001) 42986-42993
216. Puttaraju M., Jamison S.F., Mansfield S.G., Garcia-Blanco M.A., and Mitchell L.G. Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. [Erratum in: Nat Biotechnol 1999;17:602 and Nat Biotechnol 2001;19:277]. Nat Biotechnol 17 (1999) 246-252
217. Rodriguez-Martin T., Garcia-Blanco M.A., Mansfield S.G., et al. Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. Proc Natl Acad Sci U S A 102 (2005) 15659-15664
218. Liu X., Jiang Q., Mansfield S.G., et al. Partial correction of endogenous ΔF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat Biotechnol 20 (2002) 47-52
219. Chao H., Mansfield S.G., Bartel R.C., et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med 9 (2003) 1015-1019
220. Ishihara T., Hong M., Zhang B., et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24 (1999) 751-762
221. Parness J., and Horwitz S.B. Taxol binds to polymerized tubulin in vitro. J Cell Biol 91 (1981) 479-487
222. Zhang B., Maiti A., Shively S., et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A 102 (2005) 227-231
223. Michaelis M.L., Seyb K.I., and Ansar S. Cytoskeletal integrity as a drug target. Curr Alzheimer Res 2 (2005) 227-229
224. Michaelis M.L. Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice. Curr Alzheimer Res 3 (2006) 215-219
225. Matsuoka Y., Jouroukhin Y., Gray A.J., et al. A neuronal microtubule interacting agent, NAP, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 325 (2008) 146-153
226. Roberson E.D., Scearce-Levie K., Palop J.J., et al. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007) 750-754
227. Hutton M. Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 56 (2001) S21-S25